George DJ, Hessel C, Halabi S, et al. - Given that the phase II CABOSUN trial revealed prolonged progression-free survival (PFS) and improved objective response rate (ORR) with cabozantinib treatment vs sunitinib in patients with advanced renal cell carcinoma of intermediate or poor risk by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria, researchers performed this inquiry to analyze PFS and ORR, both determined by independent radiology committee, by subgroups of baseline features. In a randomized manner 1:1, a total of 157 patients in the CABOSUN trial were assigned to receive cabozantinib or sunitinib, stratified by IMDC risk group and presence of bone metastases. Findings revealed generally improved PFS and ORR in correlation with cabozantinib treatment vs sunitinib across subgroups, including in groups defined by IMDC risk group, bone metastases, age, and tumor burden.